AC
ACRV.O
—
NASDAQ
Biotechnology & Medical Research
Acrivon Therapeutics Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
66,8M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-69,2 %
Net margin
—
Debt / equity
0,00
Beta
—
52w range
—
Volume
3
Day range
—
Prev close
$1,67
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Acrivon Therapeutics Inc is a biotechnology company focused on the development of novel therapeutics for the treatment of respiratory diseases, primarily through its lead product candidate, ACR-161, an inhaled corticosteroid.
Business. Acrivon Therapeutics Inc (ACRV.O) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
BUY8 analysts
8 buy0 hold0 sell
Avg 12m price target12,25
Analyst recommendations
8 analysts · consensus BuyBuy8
Hold0
Sell0
12-month price target
12,25
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
8 analysts · indicative
Ownership→
Wellington Management Company, LLP
largest disclosed fund holder
Profitability→
-69,2 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to ACRV.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Acrivon Therapeutics Inc (ACRV.O) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
AI synthesis
GENERATEDAcrivon Therapeutics Inc has a market capitalization of $82.18 million and a price-to-book ratio of 0.73, indicating that the company is trading at a discount to its book value. The company's liquidity position is strong, with a current ratio of 7.69, and it holds $41.50 million in cash and equivalents, while having no long-term debt. The company's equity base is $112.52 million, and its total liabilities are relatively low at $17.20 million.
The company's profitability is currently negative, with a net loss of $77.91 million and an operating loss of $84.11 million in the latest period. Its return on equity is -69.24%, and its return on assets is -60.06%, both significantly below the industry median for biotechnology firms. The company's operating cash flow is negative at -$63.67 million, and its free cash flow is -$78.17 million, indicating that it is not generating positive cash from operations.
Acrivon Therapeutics Inc is a single-segment company, with all of its operations focused on the development of respiratory therapeutics. The company does not disclose geographic revenue breakdowns, but its operations are primarily based in the United States. The company's revenue is not disclosed, but its financials suggest it is in the pre-revenue or early-stage development phase.
The company's growth trajectory is not yet defined in terms of revenue, as it is not currently generating revenue. However, its capital expenditures of -$1.67 million suggest ongoing investment in development activities. Analysts have assigned a mean price target of $12.25, with a median of $11.00, indicating a potential upside of over 500% from the current market price of $1.92.
The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. The company has no long-term debt and a strong cash position, which reduces its financial risk. However, the company's reliance on equity financing and the absence of revenue introduce operational and dilution risks in the long term.
Recent events include the continued development of ACR-161, with no major regulatory or clinical setbacks reported in the latest filings. The company has not issued any new shares in the recent period, and there are no immediate signs of dilution pressure.
Key takeaways
- Acrivon Therapeutics Inc is a pre-revenue biotechnology company with a strong cash position and no long-term debt.
- The company is trading at a significant discount to book value, with a price-to-book ratio of 0.73.
- Analysts have assigned a mean price target of $12.25, suggesting a potential upside of over 500% from the current market price.
- The company's financials indicate a high level of operational risk, with significant net and operating losses.
- The company's risk profile is currently low in terms of liquidity and dilution, but its long-term viability depends on successful product development and commercialization.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$1,56
Market cap
$82.2M
Enterprise valueⓘ
$40.7M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
0.7x
P / Tangible bookⓘ
0.7x
Tangible book
$112.5M
Net cashⓘ
$41.5M
Current ratioⓘ
7.7
Debt / equityⓘ
0.0
ROAⓘ
-60.1%
ROEⓘ
-69.2%
Cash conversionⓘ
82.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures
Subsidiaries1
EX21:740c9e434512EX21:740c9e434512Subsidiarie97%
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-2,18
Predicted surprise
+0,00
Beat probability
45 %
Analysts
8
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-16 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -2,18 |
| Revenue | —no estimate | —no estimate | 1,5M USD |
| Operating income | —no estimate | —no estimate | -92,3M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution8 analysts
Strong buy2
Buy6
Hold0
Sell0
Strong sell0
12-month price target$12,25 · Median $11,00
Low $8,00High $19,00
Operating income · consensus-92,3M USD
EPS surprise
+7,2 %
reported vs consensus · beat
Revenue surprise
−100,0 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$8,00
Mean$12,25
Median$11,00
High$19,00
Spot$1,56
+685.3 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
ROE-69,2 %Bottom quartile
D/E0,00Above median
Cash Conv0,82Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 141 925 sh7 grants7 insiders
- Director · Stock Option (Right to Buy) → Common StockAcquired 20 275 @ $1,52grant · 2026-06-17
- Director, 10% owner · Stock Option (Right to Buy) → Common StockAcquired 20 275 @ $1,52grant · 2026-06-17
- Director · Stock Option (Right to Buy) → Common StockAcquired 20 275 @ $1,52grant · 2026-06-17
- Director · Stock Option (Right to Buy) → Common StockAcquired 20 275 @ $1,52grant · 2026-06-17
- Director · Stock Option (Right to Buy) → Common StockAcquired 20 275 @ $1,52grant · 2026-06-17
- Director · Stock Option (Right to Buy) → Common StockAcquired 20 275 @ $1,52grant · 2026-06-17
- Director · Stock Option (Right to Buy) → Common StockAcquired 20 275 @ $1,52grant · 2026-06-17
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Source documents
- Acrivon Therapeutics Inc Market data — financials · 2026-05-27
- Acrivon Therapeutics Inc Market data — analyst estimates · 2026-05-27
- Acrivon Therapeutics Inc Market data — ESG · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-06-300,00 %$4M
- Investment Managers · as of 2025-12-310,00 %$2M
- Investment Managers · as of 2024-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
Mixed / flat0 buys · 0 sellsnet $014 insiders · last 365d
- Director, President and CEO · Common StockOther 13 729 @ $1,79$25K · 2026-05-21
- Chief Development Officer · Common StockOther 38 584 · 2026-05-18
- Chief Operating Officer · Common StockOther 72 981 · 2026-05-18
- Director, President and CEO · Common StockOther 180 095 · 2026-05-18
- Director, President and CEO · Common StockOther 72 706 · 2026-05-18
- Director · Common StockOther 9 366 · 2026-05-18
- Director · Common StockOther 9 366 · 2026-05-18
- Chief Accounting Officer · Common StockOther 14 227 · 2026-05-18
- Chief Medical Officer · Common StockOther 38 817 · 2026-05-18
- Chief Legal Officer · Common StockOther 49 830 · 2026-05-18
- Chief Financial Officer · Common StockOther 46 167 · 2026-05-18
- Director · Common StockOther 9 366 · 2026-05-18
- Director · Common StockOther 9 366 · 2026-05-18
- Director, 10% owner · Common StockOther 9 366 · 2026-05-18
- Director · Common StockOther 9 366 · 2026-05-18
- Director · Common StockOther 9 366 · 2026-05-18
- Chief Legal Officer · Common StockOther 184 @ $1,92$353 · 2026-05-14
- Chief Accounting Officer · Common StockOther 99 @ $1,92$190 · 2026-05-14
- Chief Development Officer · Common StockOther 404 @ $1,92$776 · 2026-05-14
Short positioning
1.5Mshares short-47.6% vs prior
2.34days to cover
40.0%short of daily vol
2fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
ACRV.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorSubsidiaries
Evidence & claims
From filings & derived data- Current ratio (FY 2025-12-31): 7.69xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -39.7%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.15xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 4.2%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 15.1%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 15.1%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 3.3%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 3.1%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -34.0%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -13.1%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -6.3%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -36.4%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 5.7%Derived (calculated)
- Return on equity (FY 2025-12-31): -69.2%Derived (calculated)
- Return on assets (FY 2025-12-31): -60.1%Derived (calculated)
- Capex (annual): USD 1.67MSEC XBRL filing
- Net income (annual): USD -77.91MSEC XBRL filing
- Operating income (annual): USD -84.11MSEC XBRL filing
- Shareholders' equity (annual): USD 112.52MSEC XBRL filing
- Cash & equivalents (annual): USD 41.5MSEC XBRL filing
- Total assets (annual): USD 129.72MSEC XBRL filing
- Current liabilities (annual): USD 15.66MSEC XBRL filing
- Shares outstanding (annual): 31.65MSEC XBRL filing
- Operating cash flow (annual): USD -63.66MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-17 00:00 UTCINSIDER7 insider transactions — 2026-06 7 derivative
2026-06-17INSIDERPalani Santhosh acquired 20.3k sh Stock Option (Right to Buy) — Director
2026-06-17INSIDERRA CAPITAL MANAGEMENT, L.P. acquired 20.3k sh Stock Option (Right to Buy) — Director, 10% owner
2026-06-17INSIDERTOMSICEK MICHAEL JOHN acquired 20.3k sh Stock Option (Right to Buy) — Director
2026-06-17INSIDERShacham Sharon acquired 20.3k sh Stock Option (Right to Buy) — Director
2026-06-17INSIDERMagovcevic-Liebisch Ivana acquired 20.3k sh Stock Option (Right to Buy) — Director
2026-06-17INSIDERDiRocco Derek acquired 20.3k sh Stock Option (Right to Buy) — Director
2026-06-17INSIDERBAUM CHARLES M acquired 20.3k sh Stock Option (Right to Buy) — Director
2026-05-21 00:00 UTCINSIDER19 insider transactions — 2026-05
2026-05-21INSIDERBlume-Jensen Peter transacted 13.7k sh — Director, President and CEO ~$25k
2026-05-18INSIDERGamelin Erick transacted 38.6k sh — Chief Development Officer
2026-05-18INSIDERRA CAPITAL MANAGEMENT, L.P. transacted 9.4k sh — Director, 10% owner
2026-05-18INSIDERTOMSICEK MICHAEL JOHN transacted 9.4k sh — Director
2026-05-18INSIDERShacham Sharon transacted 9.4k sh — Director
2026-05-18INSIDERPalani Santhosh transacted 9.4k sh — Director
2026-05-18INSIDERMagovcevic-Liebisch Ivana transacted 9.4k sh — Director
2026-05-18INSIDERDiRocco Derek transacted 9.4k sh — Director
2026-05-18INSIDERBAUM CHARLES M transacted 9.4k sh — Director
2026-05-18INSIDERPeterson Katharine transacted 14.2k sh — Chief Accounting Officer
2026-05-18INSIDERMirza Mansoor Raza transacted 38.8k sh — Chief Medical Officer
2026-05-18INSIDERMiller Mary transacted 49.8k sh — Chief Legal Officer
2026-05-18INSIDERLevy Adam D. transacted 46.2k sh — Chief Financial Officer
2026-05-18INSIDERDevroe Eric transacted 73.0k sh — Chief Operating Officer
2026-05-18INSIDERBlume-Jensen Peter transacted 180.1k sh — Director, President and CEO
2026-05-18INSIDERBlume-Jensen Peter transacted 72.7k sh — Director, President and CEO
2026-05-14INSIDERGamelin Erick transacted 404 sh — Chief Development Officer ~$1k
2026-05-14INSIDERMiller Mary transacted 184 sh — Chief Legal Officer ~$0k
2026-05-14INSIDERPeterson Katharine transacted 99 sh — Chief Accounting Officer ~$0k
Showing the 40 most recent of 42 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage